Tesamorelin: The Growth Hormone Peptide With an Actual FDA Approval

Tesamorelin occupies unusual territory. Nearly everything else discussed in this series is investigational. Tesamorelin is an FDA-approved drug, marketed as Egrifta — but the approval is narrower than the way it’s usually marketed, and understanding that gap is the whole point of this article.

What it’s actually approved for

Tesamorelin is approved to reduce excess abdominal fat in adults with HIV-associated lipodystrophy — a condition in which visceral fat accumulates around the organs. It went through full clinical trials for that indication and demonstrated meaningful, measurable reduction in visceral adipose tissue.

That is a real approval built on real data. It is also a specific population. When tesamorelin is prescribed to a perimenopausal woman for midsection changes, that is an off-label use — legal and common in medicine, but it means the evidence supporting it is inferred rather than direct.

Visceral fat, and why it’s the right target

Not all abdominal fat is equivalent. Subcutaneous fat sits under the skin. Visceral fat sits deeper, wrapped around the organs, and behaves like an active endocrine tissue — producing inflammatory signals and driving insulin resistance. It is the fat most strongly linked to cardiometabolic risk.

Here is why this lands for midlife women. As estrogen declines, fat distribution shifts. Fat that once sat on hips and thighs relocates toward the abdomen, and a meaningful share of that is visceral. Women describe it as their body changing shape without their habits changing at all — and they’re describing something real.

Tesamorelin works as a growth hormone releasing hormone analog, prompting the pituitary to release growth hormone in pulses. Growth hormone has a particular effect on visceral fat metabolism, which is the mechanism behind the trial results.

“My body changed shape and I didn’t change anything” is not a failure of discipline. It is what declining estrogen does to fat distribution.

How it compares to the other options

Versus sermorelin or CJC-1295 + Ipamorelin: all three work through growth hormone release. Tesamorelin is distinguished by having dedicated clinical trial data specifically on visceral fat.

Versus the GLP-1 medications: different tools for different jobs. GLP-1s produce substantial total weight loss through appetite regulation. Tesamorelin targets a specific fat compartment without appetite suppression. If your concern is overall weight, that’s a GLP-1 conversation. If your labs show metabolic risk concentrated in visceral fat while your total weight is reasonable, tesamorelin becomes the more precise question.

What to measure first

Visceral fat should be assessed, not assumed from the mirror. Waist circumference is a reasonable proxy; body composition scanning is better. Alongside it: fasting insulin, HbA1c, a lipid panel, liver enzymes, and sex hormones appropriate to your stage.

The reason matters. If insulin resistance is driving visceral accumulation and the insulin resistance is itself downstream of a hormonal transition, then addressing hormones, resistance training, and protein intake changes the terrain that any peptide would be working against.

Frequently Asked Questions

Will it help me lose weight overall?

It is not a general weight-loss drug. The evidence concerns visceral fat specifically, and total weight change in the trials was modest.

Is it better than sermorelin or CJC-1295 + Ipamorelin?

For visceral fat specifically it has the most direct evidence. For general growth hormone support the others are reasonable alternatives.

What happens if I stop?

Trial data in the approved population showed visceral fat returning after discontinuation. This is maintenance, not cure.

Can I combine it with a GLP-1?

They act differently and are sometimes considered together, but the combination needs deliberate design and monitoring by your prescribing provider — particularly around glucose metabolism and protein intake.